BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18566816)

  • 1. Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?
    Tessonnier L; Sebag F; Palazzo FF; Colavolpe C; De Micco C; Mancini J; Conte-Devolx B; Henry JF; Mundler O; Taïeb D
    Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2018-25. PubMed ID: 18566816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidental non-secreting adrenal masses in cancer patients: intra-individual comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography with computed tomography and shift magnetic resonance imaging.
    Gratz S; Kemke B; Kaiser W; Heinis J; Behr TM; Höffken H
    J Int Med Res; 2010; 38(2):633-44. PubMed ID: 20515577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
    Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.
    Nakajo M; Jinguji M; Fukukura Y; Kajiya Y; Tani A; Nakajo M; Nakabeppu Y; Arimura H; Nishio Y; Nakamura F; Yoshiura T
    Eur Radiol; 2015 Dec; 25(12):3696-705. PubMed ID: 25925356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of 18F-FDG-positron emission tomography in presurgical evaluation of nonspecific or suspectious adrenal masses in non-oncologic patients].
    Pavón-Paz I; Rosado-Sierra JA; Balsa-Bretón MÁ; Guijarro-Armas G; Merino-Viveros M; Penín-Gonzalez FJ
    Med Clin (Barc); 2016 Feb; 146(3):104-7. PubMed ID: 26343158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning.
    Han SJ; Kim TS; Jeon SW; Jeong SJ; Yun M; Rhee Y; Kang ES; Cha BS; Lee EJ; Lee HC; Lim SK
    Int J Clin Pract; 2007 May; 61(5):802-9. PubMed ID: 17343665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study.
    Guerin C; Pattou F; Brunaud L; Lifante JC; Mirallié E; Haissaguerre M; Huglo D; Olivier P; Houzard C; Ansquer C; Hindié E; Loundou A; Archange C; Tabarin A; Sebag F; Baumstarck K; Taïeb D
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2465-2472. PubMed ID: 28431167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.
    Koopman D; van Dalen JA; Stigt JA; Slump CH; Knollema S; Jager PL
    Ann Nucl Med; 2016 Feb; 30(2):145-52. PubMed ID: 26644009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation.
    Ansquer C; Scigliano S; Mirallié E; Taïeb D; Brunaud L; Sebag F; Leux C; Drui D; Dupas B; Renaudin K; Kraeber-Bodéré F
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(9):1669-78. PubMed ID: 20490488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of unenhanced computed tomography and
    Delivanis DA; Bancos I; Atwell TD; Schmit GD; Eiken PW; Natt N; Erickson D; Maraka S; Young WF; Nathan MA
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):30-36. PubMed ID: 28815667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients.
    Lu Y; Xie D; Huang W; Gong H; Yu J
    Neoplasma; 2010; 57(2):129-34. PubMed ID: 20099976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of lipid-rich adrenal tumors by FDG PET/CT: Are they hormone-secreting or not?
    Takanami K; Kaneta T; Morimoto R; Satoh F; Nakamura Y; Takase K; Takahashi S
    Ann Nucl Med; 2014 Feb; 28(2):145-53. PubMed ID: 24272068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients.
    Boland GW; Blake MA; Holalkere NS; Hahn PF
    AJR Am J Roentgenol; 2009 Apr; 192(4):956-62. PubMed ID: 19304700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk stratification of adrenal masses by [
    Salgues B; Guerin C; Amodru V; Pattou F; Brunaud L; Lifante JC; Mirallié E; Sahakian N; Castinetti F; Loundou A; Baumstarck K; Sebag F; Taïeb D
    Clin Endocrinol (Oxf); 2021 Feb; 94(2):133-140. PubMed ID: 32978795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET/CT in the evaluation of adrenal masses.
    Metser U; Miller E; Lerman H; Lievshitz G; Avital S; Even-Sapir E
    J Nucl Med; 2006 Jan; 47(1):32-7. PubMed ID: 16391184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
    Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
    Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.
    Yun M; Kim W; Alnafisi N; Lacorte L; Jang S; Alavi A
    J Nucl Med; 2001 Dec; 42(12):1795-9. PubMed ID: 11752075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.